全国范围内多发性与首发性皮肤鳞状细胞癌的发病率及未来发病趋势预测
结果显示cSCC发病率持续上升,女性增幅最高(2002至2017年年增8.2%),且多发性cSCC显著增加医疗负担,未来十年男性ESR将增至132.4/10万人年,女性增至88.9/10万人年。
要点
- cSCC年龄标化发病率持续上升,女性2002至2017年年增8.2%
- 2017年首发性cSCC的ESR男性107.6、女性68.7每10万人年
- 计入多发性cSCC后,ESR男性增至170.4、女性增至92.6每10万人年
核心结论
- cSCC发病率持续上升,女性尤为显著,多发性cSCC显著增加当前和未来的皮肤科医疗负担。
- 需修订皮肤癌政策以遏制这一上升趋势。
研究设计与样本
- 同时纳入2017年诊断的多发性cSCC患者,按性别、年龄组、身体部位和疾病分期计算年龄标化发病率。
- 拟合正斜率回归模型估计至2027年的cSCC发病率。
主要发现
- 2002至2017年女性ESR年增幅最高,为8.2%(95%CI,7.6%-8.8%)。
- 2017年首发性cSCC的ESR男性为107.6/10万人年(1989年40.0),女性为68.7/10万人年(1989年13.9);对应美国标化率男性71.4/10万人年、女性46.4/10万人年。
- 计入多发性cSCC后,ESR男性增加58.4%(107.6增至170.4/10万人年),女性增加34.8%(68.7增至92.6/10万人年)。
- 预测未来十年ESR男性进一步增加23.0%至132.4/10万人年(95%预测区间125.8-139.0),女性增加29.4%至88.9/10万人年(95%预测区间84.3-93.5)。
临床怎么用
- 临床应关注cSCC患者的多发性病变风险,尤其是女性患者发病率快速上升。
- 皮肤科医疗规划需考虑多发性cSCC带来的长期随访和治疗负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Until now, most studies on cutaneous squamous cell carcinoma (cSCC) incidence rates concerned only the first cSCC per patient. Given the increase in incidence rates and the frequent occurrence of subsequent cSCCs per patient, population-based data on the incidence rates of both first and multiple cSCCs are needed. OBJECTIVES: To calculate annual age-standardized incidence rates for histopathologically confirmed first and multiple cSCCs per patient and to estimate future cSCC incidence rates up to 2027. DESIGN, SETTING, AND PARTICIPANTS: A nationwide population-based epidemiologic cohort study used cancer registry data on 145 618 patients with a first histopathologically confirmed cSCC diagnosed between January 1, 1989, and December 31, 2017, from the Netherlands Cancer Registry and all patients with multiple cSCCs diagnosed in 2017. MAIN OUTCOMES AND MEASURES: Age-standardized incidence rates for cSCC-standardized to the European Standard Population 2013 and United States Standard Population 2000-were calculated per sex, age group, body site, and disease stage. A regression model with positive slope was fitted to estimate cSCC incidence rates up to 2027. RESULTS: A total of 145 618 patients in the Dutch population (84 572 male patients [58.1%]; mean [SD] age, 74.5 [11.5] years) received a diagnosis of a first cSCC between 1989 and 2017. Based on incident data, European Standardized Rates (ESRs) increased substantially, with the highest increase found among female patients from 2002 to 2017, at 8.2% (95% CI, 7.6%-8.8%) per year. The ESRs for first cSCC per patient in 2017 were 107.6 per 100 000 person-years (PY) for male patients, an increase from 40.0 per 100 000 PY in 1989, and 68.7 per 100 000 PY for female patients, an increase from 13.9 per 100 000 PY in 1989, which corresponds with a US Standardized Rate of 71.4 per 100 000 PY in 2017 for men and 46.4 per 100 000 PY in 2017 for women. Considering multiple cSCCs per patient, ESRs increased by 58.4% for men (from 107.6 per 100 000 PY to 170.4 per 100 000 PY) and 34.8% for women (from 68.7 per 100 000 PY to 92.6 per 100 000 PY). Estimation of ESRs for the next decade show a further increase of 23.0% for male patients (ESR up to 132.4 per 100 000 PY [95% prediction interval, 125.8-139.0 per 100 000 PY]) and 29.4% for female patients (ESR up to 88.9 per 100 000 PY [95% prediction interval, 84.3-93.5 per 100 000 PY]). CONCLUSIONS AND RELEVANCE: This nationwide epidemiologic cohort study suggests that incidence rates of cSCC keep increasing, especially among female patients, and that the occurrence of multiple cSCCs per patient significantly adds to the current and future burden on dermatologic health care. Revision of skin cancer policies are needed to halt this increasing trend.
引用
- Tokez S, Hollestein L, Louwman M, et al. Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2020. PMID: 33112377. doi:10.1001/jamadermatol.2020.3677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。